Understanding combination therapy with biologics and immunosuppressives for the treatment of Crohn's disease

Gastroenterology and Hepatology

Volumn 6, Issue 8, 2010, Pages 486-490

  Colombel, Jean Frederic ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE;

CANCER RISK; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; NOTE; T CELL LYMPHOMA; TREATMENT OUTCOME;

EID: 77957002842     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Van Assche G, Magelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861-1868. (Pubitemid 351790744)
2. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
3. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30:210-226.
4. Lichtenstein G, Cohen RD, Feagan BG, et al. Risk factors for serious infections in patients receiving infliximab and other Crohn's disease therapies: TREAT™ Registry Data. Presented at Digestive Disease Week; May 2-5, 2010; New Orleans, LA. Poster T1039.
5. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010 Jun 29. [Epub ahead of print].